Founded in 2019, Superbiotics’ mission is to develop innovative technologies and produce and formulate microbiotic solutions (blends and single strains) comprising live probiotic strains. The company also aims to valorize and patent processes or strains that have demonstrated a significant impact on human and animal health through the study of in vitro and ex vivo models, as well as in vivo in animals and humans. The identification of new physiological functionalities will enable the formulation of high value-added compounds.
Building on the expertise of Vésale Pharma, Superbiotics, owner of innovative probiotic strains, offers a wide range of probiotic products for digestive health, pediatrics, immunity and women’s well-being. Superbiotics’ commitment to quality is reflected in its rigorous selection of strains and patented INTELICAPS® encapsulation technology (property of Vésale Pharma), which guarantees the viability and efficacy of its probiotics.
With a global presence in Europe, the United States, Asia and the Middle East, Superbiotics is dedicated to improving health and well-being through innovative probiotic solutions.
Creation of Superbiotics SRL
Right of utilisation of the Vésale Pharma patented probiotic micro-encapsulation process (INTELICAPS®) that protects probiotics from humidity and heat. The process also protects bacteria from gastric acid and pancreatic juice without altering their functionality.
Wagralim cluster – ongoing project
Within the SuNup project, Superbiotics aims to replace the freeze-drying method of its Intelicaps process with faster, less energy-intensive alternatives. This objective also involves developing standardized micro-encapsulation methods suitable for the probiotic strains commercialized by the company.
Wagralim cluster – project completed in 2022
The main aim of the project was to develop innovative “synbiotics”, combining probiotics and prebiotics to protect piglets from birth to slaughter, thanks to the effect of synbiotics on the intestinal microbiota.
The positive effects of the Bf animalis lactis VES 002 strain have been demonstrated in preventing diarrhoea and improving growth in piglets.
Wagralim cluster – ongoing project
Within the Biotech4Food project, Superbiotics aims to enhance the efficiency of its manufacturing processes, particularly by replacing the freeze-drying method with less energy-intensive alternatives. Additionally, the project focuses on improving the stability and extending the shelf life of its microbiotic products. »
Move out of the company in the Crealys Parc, Isnes, Belgium.
Wagralim cluster – project awarded in January 2025
Studying the effects of a probiotic administered to pregnant women on infants’ immunity.
Superbiotics will continue its research regarding its proprietary strains and micro-encapsulation, focusing on 3 areas (women’s health, digestive health and paediatrics).
The strains marketed by Superbiotics have the following characteristics :
CEO
COO
Finance & Admin Director
Production Manager
m
Laboratory Expert
m
QA/RA Manager & Project Manager
Director of Public Funding & Research Contracting
If you are an agent, distributor or want to promote our products internationally.
Pioneering Probiotic Solutions For A Healthier Tomorrow.
We specialise in microencapsulated live bacteria for human and animal health and food applications.